{"id":"olz-sam","safety":{"commonSideEffects":[{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1235831","moleculeType":"Small molecule","molecularWeight":"398.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Olanzapine is an atypical antipsychotic that acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. Samidorphan is a partial agonist at the μ-opioid receptor, which helps to mitigate the weight gain associated with olanzapine.","oneSentence":"OLZ/SAM is an oral, fixed-dose combination of olanzapine and samidorphan, a partial agonist at the μ-opioid receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:11.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"}]},"trialDetails":[{"nctId":"NCT04987229","phase":"PHASE3","title":"Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"Alkermes, Inc.","startDate":"2021-10-22","conditions":"Bipolar I Disorder, Schizophrenia","enrollment":236},{"nctId":"NCT05303064","phase":"PHASE3","title":"Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder","status":"RECRUITING","sponsor":"Alkermes, Inc.","startDate":"2022-06-30","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":220},{"nctId":"NCT04987658","phase":"PHASE1","title":"Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2021-07-22","conditions":"Bipolar I Disorder","enrollment":7},{"nctId":"NCT05547100","phase":"PHASE1","title":"Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2022-09-14","conditions":"Focus of Study is on Healthy Lactating Women","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALKS 3831","ALKS 3831, LYBALVI"],"phase":"phase_3","status":"active","brandName":"OLZ/SAM","genericName":"OLZ/SAM","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OLZ/SAM is an oral, fixed-dose combination of olanzapine and samidorphan, a partial agonist at the μ-opioid receptor. Used for Treatment of schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}